View in EDS

First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.

Saved in:
Bibliographic Details
Title: First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.
Authors: Yarchoan M; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland., Powderly JD; Carolina BioOncology Institute, Huntersville, North Carolina., Bastos BR; Baptist Health Miami Cancer Institute, Miami, Florida., Karasic TB; Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania., Crysler OV; University of Michigan Rogel Cancer Center, Ann Arbor, Michigan., Munster PN; UCSF Health - UCSF Medical Center, San Francisco, California., McKean MA; Sarah Cannon Research Institute, Nashville, Tennessee., Emens LA; UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania., Saenger YM; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York., Ged Y; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland., Stagg R; Tempest Therapeutics, Brisbane, California., Smith S; Tempest Therapeutics, Brisbane, California., Whiting CC; Tempest Therapeutics, Brisbane, California., Moon A; Tempest Therapeutics, Brisbane, California., Prasit P; Tempest Therapeutics, Brisbane, California., Jenkins Y; Tempest Therapeutics, Brisbane, California., Standifer N; Tempest Therapeutics, Brisbane, California., Dubensky TW; Tempest Therapeutics, Brisbane, California., Whiting SH; Tempest Therapeutics, Brisbane, California., Ulahannan SV; Stephenson Cancer Center of the University of Oklahoma/Sarah Cannon Research Institute, Oklahoma City, Oklahoma.
Source: Cancer research communications [Cancer Res Commun] 2024 Apr 18; Vol. 4 (4), pp. 1100-1110.
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9918281580506676 Publication Model: Print Cited Medium: Internet ISSN: 2767-9764 (Electronic) Linking ISSN: 27679764 NLM ISO Abbreviation: Cancer Res Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38551394
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Yarchoan+M%22">Yarchoan M</searchLink>; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.<br /><searchLink fieldCode="AU" term="%22Powderly+JD%22">Powderly JD</searchLink>; Carolina BioOncology Institute, Huntersville, North Carolina.<br /><searchLink fieldCode="AU" term="%22Bastos+BR%22">Bastos BR</searchLink>; Baptist Health Miami Cancer Institute, Miami, Florida.<br /><searchLink fieldCode="AU" term="%22Karasic+TB%22">Karasic TB</searchLink>; Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Crysler+OV%22">Crysler OV</searchLink>; University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.<br /><searchLink fieldCode="AU" term="%22Munster+PN%22">Munster PN</searchLink>; UCSF Health - UCSF Medical Center, San Francisco, California.<br /><searchLink fieldCode="AU" term="%22McKean+MA%22">McKean MA</searchLink>; Sarah Cannon Research Institute, Nashville, Tennessee.<br /><searchLink fieldCode="AU" term="%22Emens+LA%22">Emens LA</searchLink>; UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Saenger+YM%22">Saenger YM</searchLink>; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York.<br /><searchLink fieldCode="AU" term="%22Ged+Y%22">Ged Y</searchLink>; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.<br /><searchLink fieldCode="AU" term="%22Stagg+R%22">Stagg R</searchLink>; Tempest Therapeutics, Brisbane, California.<br /><searchLink fieldCode="AU" term="%22Smith+S%22">Smith S</searchLink>; Tempest Therapeutics, Brisbane, California.<br /><searchLink fieldCode="AU" term="%22Whiting+CC%22">Whiting CC</searchLink>; Tempest Therapeutics, Brisbane, California.<br /><searchLink fieldCode="AU" term="%22Moon+A%22">Moon A</searchLink>; Tempest Therapeutics, Brisbane, California.<br /><searchLink fieldCode="AU" term="%22Prasit+P%22">Prasit P</searchLink>; Tempest Therapeutics, Brisbane, California.<br /><searchLink fieldCode="AU" term="%22Jenkins+Y%22">Jenkins Y</searchLink>; Tempest Therapeutics, Brisbane, California.<br /><searchLink fieldCode="AU" term="%22Standifer+N%22">Standifer N</searchLink>; Tempest Therapeutics, Brisbane, California.<br /><searchLink fieldCode="AU" term="%22Dubensky+TW%22">Dubensky TW</searchLink>; Tempest Therapeutics, Brisbane, California.<br /><searchLink fieldCode="AU" term="%22Whiting+SH%22">Whiting SH</searchLink>; Tempest Therapeutics, Brisbane, California.<br /><searchLink fieldCode="AU" term="%22Ulahannan+SV%22">Ulahannan SV</searchLink>; Stephenson Cancer Center of the University of Oklahoma/Sarah Cannon Research Institute, Oklahoma City, Oklahoma.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229918281580506676%22">Cancer research communications</searchLink> [Cancer Res Commun] 2024 Apr 18; Vol. 4 (4), pp. 1100-1110.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%22">American Association for Cancer Research </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9918281580506676 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2767-9764 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2227679764%22">27679764 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Res Commun <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38551394
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/2767-9764.CRC-24-0082
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1100
    Titles:
      – TitleFull: First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Yarchoan M
      – PersonEntity:
          Name:
            NameFull: Powderly JD
      – PersonEntity:
          Name:
            NameFull: Bastos BR
      – PersonEntity:
          Name:
            NameFull: Karasic TB
      – PersonEntity:
          Name:
            NameFull: Crysler OV
      – PersonEntity:
          Name:
            NameFull: Munster PN
      – PersonEntity:
          Name:
            NameFull: McKean MA
      – PersonEntity:
          Name:
            NameFull: Emens LA
      – PersonEntity:
          Name:
            NameFull: Saenger YM
      – PersonEntity:
          Name:
            NameFull: Ged Y
      – PersonEntity:
          Name:
            NameFull: Stagg R
      – PersonEntity:
          Name:
            NameFull: Smith S
      – PersonEntity:
          Name:
            NameFull: Whiting CC
      – PersonEntity:
          Name:
            NameFull: Moon A
      – PersonEntity:
          Name:
            NameFull: Prasit P
      – PersonEntity:
          Name:
            NameFull: Jenkins Y
      – PersonEntity:
          Name:
            NameFull: Standifer N
      – PersonEntity:
          Name:
            NameFull: Dubensky TW
      – PersonEntity:
          Name:
            NameFull: Whiting SH
      – PersonEntity:
          Name:
            NameFull: Ulahannan SV
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 18
              M: 04
              Text: 2024 Apr 18
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 2767-9764
          Numbering:
            – Type: volume
              Value: 4
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Cancer research communications
              Type: main
ResultId 1